Simpson edited version
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
656
On Slideshare
656
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The Relationship of Obesity – Cholesterol – Triglycerides to Metabolic Syndrome: Assessment and Interventions Presented by Graham Simpson, MD Institute Physician, Cenegenics ® Medical Institute
  • 2. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • Accumulating scientific research has shown that adipose tissue is an active endocrine and metabolic organ that plays a critical role in the development of cardiometabolic risk factors, diabetes and cardiovascular disease.
  • 3. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • Adipose tissue plays an important role in the development of low-grade systemic inflammation. Adipose tissue secretes a number of cytokines TNF2, IL1, IL6, adiponectin, leptin, plasminogen activator-1 – these stimulate inflammatory protein production in the liver through activation of NFKB.
  • 4. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • Macrophage accumulation in adipose tissue also promotes obesity associated inflammation and its sequelae, including endothelial dysfunction, insulin resistance, dyslipidemia, hypertension, impaired thrombolysis, diabetes and atherosclerosis.
  • 5. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • Liposuction of abdominal subcutaneous adipose tissue has been shown not to improve cardiometabolic risk factors, whereas experimental studies report that reduction of visceral fat improved glucose levels and insulin sensitivity.
  • 6. Prevalence of CAD Risk Factors
  • 7. Parallels
  • 8. Relative Risk of CAD Mortality
  • 9. Metabolic Syndrome
  • 10. Associations
  • 11. Mechanisms of Dyslipidemia
  • 12. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • ASSESSMENT
          • Blood tests
          • Tape measure
          • Dexa scan
          • IMT
          • Vascular reactivity (FMD)
  • 13. Patient Overview     AVERAGE MIN MAX Age   51.8 28 73 Married   139 total     Children   2.4 0 15           Ht   70.8 60.4 78.8 Wt   212.7 134 344.5 % body fat   30.3 9.2 44.2 Densitometer   none = 95 Penia = 83 Porosis = 20 Depression   8.3 0 32 QLI   6.6 0 22           Glucose   95.3 65 245 A1C   5.6 4.6 11.2 M Gluc   123.2 86 321 F Insulin   7.6 1 59 Uric Acid   6.6 1.6 11.8 Homo   9.9 3.8 20.5 CRP   3.0 0.1 37.8           Chol   197.5 109 331 TG   151.4 39 975 HDL   49.7 31 99 LDL   121.3 40 235           Total Test   428.6 29 966 Free Test   67.2 5.6 936 DHT   37.8 2 182 E2   23.7 1 158 IGF   159.8 66 315 PSA   1.2 0.1 5.3 DHEA   163.5 2.5 1210 TSH   2.42 0.7 12.66
  • 14.
  • 15. What is IMT?
    • IMT measured the Intima-Media Thickness (IMT) of the common carotid
      • Determines the presence and severity of atherosclerosis
    • IMT of the carotid artery has been conclusively demonstrated as a surrogate endpoint for cardiovascular disease (CVD)
    • IMT evaluates CVD itself instead of the risk factors for the disease
  • 16. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • INTERVENTION
            • Lifestyle
            • Paleo-Nutrition
            • Nutraceuticals
            • Exercise
            • Detoxification
            • Mind-Body Rx
            • Hormone Restoration
            • Pharmaceuticals
  • 17. Exhaustive, Scholarly Work
  • 18. Eukaryotes
  • 19. Paleolithic Nutrition A Consideration of Its Nature and Current Implications S. Boyd Eaton, MD, and Melvin Konner, PhD NEJM 31Jan85 Vol 312 No.5
  • 20. Ancestral vs. Modern Humans
  • 21. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • PHARMACEUTICALS
          • Metformin
          • Orlistat
          • Niacin
          • Statins
          • Omega 3 fatty acids
          • Fibrates
            • Gemfibrozil
            • Fenofibrate
  • 22. Potential Mechanisms
  • 23. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome
    • PHARMACEUTICALS, cont’d
          • Cholesteryl Ester Transfer Protein Inhibitor (CETP)
            • Torcetrapib (discontinued)
            • JTT-705
          • Endocannabinoid Receptor Antagonism
            • Rimonabant (first CB1 antagonist)
          • Thiazolidinediones
            • Pioglitazone
          • Obesity Drugs
            • Sibutramine (Meridia)
  • 24. Hypothetical Model
  • 25. Multisite Location
  • 26. Effects